| Source Date | Board Meeting Date | Details |
|
20-Jan-2026
|
23-Jan-2026
|
Quarterly Results
|
|
07-Nov-2025
|
12-Nov-2025
|
Quarterly Results
|
|
25-Sep-2025
|
30-Sep-2025
|
Inter alia, to consider and approve:- 1. To take on record and deliberate upon the Letter of Intent (LOI) received from Telexcell Trade PTE LTD, Singapore, for a proposed acquisition of up to 25% equity stake in Welcure Drugs & Pharmaceuticals Ltd. at an indicative price of Rs.20 per share (a substantial premium over the prevailing market price). 2. To initiate the process of comprehensive due diligence in respect of the proposed transaction, including legal, financial, and regulatory aspects. 3. To consider authorizing the Company's representatives to negotiate and finalize the terms of definitive agreements, in alignment with Welcure's long-term growth strategy and compliance with applicable regulatory frameworks. 4. To explore enabling mechanisms for shareholder approval through postal ballot / general meeting, in line with SEBI, RBI, FEMA, and stock exchange requirements. 5. To deliberate on future strategic growth opportunities in global pharmaceutical and chemical exports, leveraging Telexcell's global trade network.
|
|
11-Aug-2025
|
14-Aug-2025
|
Quarterly Results & Inter alia to consider, approve and take on record the following matters: 1. Appointment of Branch Auditors. 2. Appointment/Re-appointment of Internal Auditors. 3. Appointment of Secretarial Auditor. 4. Directors Report for the financial year 2024-2025. 5. Allotment of Equity Shares under ESOS Scheme 2021. 6. Any other matter with the permission of the Chairperson.
|
|
23-May-2025
|
28-May-2025
|
Audited Results
|
|
22-Apr-2025
|
25-Apr-2025
|
Inter alia, to consider and approve:- 1.Allotment of Equity Shares under ESOS Scheme 2021. 2.Any other matter with the permission of Chairperson.
|
|
29-Jan-2025
|
03-Feb-2025
|
Quarterly Results
|
|
18-Nov-2024
|
22-Nov-2024
|
Rights Issue & Inter alia, to consider and transact the following businesses: (1) fund raising by way of equity shares or other securities through rights issue as may be permitted under applicable law(s), subject to such regulatory/statutory approvals as may be required and other related matters.
|
|
29-Oct-2024
|
06-Nov-2024
|
Quarterly Results
|
|
06-Aug-2024
|
09-Aug-2024
|
Quarterly Results
|